Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$356.84M+1731.27%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Richard William Mark Fairman
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Employees
- 9,000
- Beta
- 1.07
- Country
- GB
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 4.33
Financials
Revenue
$356.84M+1731.3%Net Income
$7.80M+4407.9%EBITDA
$67.69M+3292.9%Free Cash Flow
$26.20M+1282.4%EPS (diluted)
$0.11+3135.3%Shares Outstanding (diluted)
71.66M+39.0%Operating Expenses
$109.78MCash & Debt
$12.30MReturn of Capital
$18.70MDividend per Share
$0.11Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $924.17M | $52.80M | $0.37 |
| 2024 | $647.30M | $6.20M | $0.09 |
| 2023 | $588.90M | $41.90M | $0.59 |
| 2022 | $554.20M | $25.70M | $0.36 |
| 2021 | $510.10M | $19.30M | $0.27 |
| 2020 | $427.80M | $5.70M | $0.08 |
| 2019 | $406.50M | $8.20M | $0.12 |
| 2018 | $327.30M | $10.70M | $0.16 |
| 2017 | $271.80M | $11.50M | $0.19 |
| 2016 | $218.10M | $7.00M | $0.12 |
| 2015 | $167.30M | $6.80M | $0.12 |
| 2014 | $142.90M | $4.80M | $0.08 |
| 2013 | $120.10M | $4.00M | $0.07 |
| 2012 | $108.75M | $2.89M | $0.05 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from CVSGF's reported EPS growth of 16.5% a year over 13 years.
- EPS in 5 years
- $1.58
- Implied price
- $53.70
- Return from $16.60
- 26.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $26.70 — today's price is already 37.8% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 24 | 29 | 34 | 39 | 44 |
|---|---|---|---|---|---|
| 6.5% | 7.8% | 12.0% | 15.6% | 18.8% | 21.7% |
| 11.5% | 12.9% | 17.2% | 21.0% | 24.4% | 27.4% |
| 16.5% | 18.0% | 22.5% | 26.5% | 30.0% | 33.2% |
| 21.5% | 23.0% | 27.8% | 31.9% | 35.6% | 38.9% |
| 26.5% | 28.1% | 33.0% | 37.3% | 41.1% | 44.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
110Social Signal Score
Mentions (2)
- Newsseekingalpha.com·5h ago·Positive
CVS Group plc (CVSGF) Q4 2026 Earnings Call Transcript CVS Group plc (CVSGF) Q4 2026 Earnings Call Transcript
View source ↗ - Newsseekingalpha.com·7h ago·Neutral
CVS Group plc (CVSGF) Q4 2026 Earnings Call Prepared Remarks Transcript CVS Group plc (CVSGF) Q4 2026 Earnings Call Prepared Remarks Transcript
View source ↗
Earnings
Thu, Sep 24(date passed)
Consensus estimate $0.61 per share
Typical surprise -5.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Feb 26$0.54 vs $0.58miss
- Tue, Oct 7$0.55 vs $0.56miss
- Thu, Feb 27$0.50 vs $0.51miss
- Thu, Sep 26$-0.14 vs $0.54miss
- Thu, Feb 29$0.56 vs $0.60miss
Estimates and results for CVSGF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in CVSGF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.